First patient treated in Stayble’s clinical phase 2b study
July 2020 RegulatoriskStayble Therapeutics announces today, July 31, 2020, that the first patient has been treated in Stayble’s clinical phase 2b study. STA363 is targeting patients suffering from chronic low back pain caused by disc degeneration.
The primary goal of the phase 2b trial is to demonstrate safety, tolerability and a clinically relevant reduction in pain in patients. The study will include some 100 patients and will be conducted at about 20 clinical sites in the Netherlands, Russia and Spain. Patients will be treated with either a high or low dose of STA363 or placebo. The longest patient follow-up is after 12 months. The study is double-blind, which means that neither the patient nor the treating physician knows whether the patient is receiving STA363 or placebo.
CEO Andreas Gerward comments: That the first patient has been treated is a noteworthy milestone that we have been working intensively to achieve. We are now looking forward to the first clinic being initiated in Spain as well as additional sites in the Netherlands and Russia and that more patients will be treated soon.
For more information
Andreas Gerward, CEO Stayble Therapeutics AB
andreas.gerward@stayble.se
+46 730 808 397